Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration

Abstract

Operationalizing the NIA-AA diagnostic criteria for clinical trial screening has the potential to substantially improve the statistical power of trials in MCI due to AD by identifying a more rapidly progressing patient population.